NASDAQ: NXGL · IEX Real-Time Price · USD
-0.029 (-1.37%)
Jul 16, 2024, 11:57 AM EDT - Market open

Company Description

NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.

It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name.

It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment.

In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019.

The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Country United States
Founded 1997
IPO Date Dec 22, 2021
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 19
CEO Adam R. Levy

Contact Details

2150 Cabot Blvd West, Suite B
Langhorne, Pennsylvania 19047
United States
Phone 215 702-8550

Stock Details

Ticker Symbol NXGL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.50
CIK Code 0001468929
CUSIP Number 65344E107
ISIN Number US65344E1073
Employer ID 26-4042544
SIC Code 3841

Key Executives

Name Position
Adam R. Levy Chief Executive Officer, President and Director
Adam E. Drapczuk III Chief Financial Officer
Gregory Robb Vice President of Operations

Latest SEC Filings

Date Type Title
Jul 8, 2024 8-K Current Report
Jun 17, 2024 8-K Current Report
Jun 13, 2024 10-K/A [Amend] Annual report
May 20, 2024 8-K Current Report
May 13, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
May 3, 2024 DEFR14A Filing
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 10, 2024 10-K Annual Report
Apr 2, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405